Abbott’s $21 billion acquisition of Exact Sciences is already reshaping its diagnostics business. In its first full quarter since the deal closed, the company reported strong growth driven by Cologuard, while outlining a broader strategy that combines stool- and blood-based colorectal cancer screening to expand its cancer diagnostics portfolio.
The article also explores Abbott’s long-term vision for colorectal cancer screening, why the company believes both testing approaches have a role despite current guideline preferences, and how recent product launches and strategic partnerships could influence the future of early cancer detection.